Ardelyx

CA - FremontBiotechnology1 H-1B visas (FY2023)

Focus: Ardelyx is a specialty biotech focused on gastrointestinal therapeutics, with commercial-stage products in IBS-C and hyperphosphatemia. The company operates as a revenue-generating specialty biotech with a concentrated product portfolio.

Gastroenterology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Ardelyx

AI assessmentNot Hiring

No open roles listed right now. Follow Ardelyx to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

IBSRELA

Irritable Bowel Syndrome with Constipation (IBS-C)

$34M Part D

Peak16.5yr

Help build intelligence for Ardelyx

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

IBSRELA is at peak revenue ($34M Part D spending) with patent protection until 2042, providing stable commercialization experience
Dual-indication tenapanor franchise (XPHOZAH in hyperphosphatemia/CKD) offers expansion opportunity beyond IBS-C leadership
27 active clinical trials across Phase 1-3 demonstrate meaningful R&D velocity in electrolyte disorders and GI conditions

Watch Out For

96% revenue concentration in single product (IBSRELA) creates extreme dependency risk if sales decline or new competition emerges
Zero active job openings at time of data capture; hiring pipeline appears stalled despite active pipeline programs
Limited publicly visible scale metrics (employee count, funding, financial data) suggest smaller organization with constrained resources

Generated by Claude from Ardelyx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Flagship product generating 96% of company revenue with long patent runway, but represents sole revenue pillar.

XPHOZAH

Hyperphosphatemia in Chronic Kidney Disease

$1M Part D

Growth16.5yr

Early-stage label expansion offering diversification potential within same tenapanor molecule, currently minimal revenue contribution.

Pipeline & Clinical Trials

RDX013

Hyperkalemia

Phase 2

Clinical Trials (1)

NCT04780841A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

Phase 2

RDX5791

Constipation Predominant Irritable Bowel Syndrome

Phase 2

Clinical Trials (3)

NCT01340053A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Phase 2

NCT02819687Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

RDX227675

Hyperkalemia

Phase 2

Clinical Trials (1)

NCT03018067A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

Phase 2

AZD1722

Irritable Bowel Syndrome With Constipation

Phase 2/3

Clinical Trials (5)

NCT01923428The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Phase 2/3

NCT02081534Dose Finding Study to Treat High Phosphate Levels in the Blood.

tenapanor

Hyperphosphatemia

Phase 4

Clinical Trials (5)

NCT03988920A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

Phase 4

NCT04549597Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 approved products, 27 clinical trials

Top TAs: Gastroenterology, Nephrology, Neurology

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Growth1 (50%)

Peak1 (50%)

2 total products

Therapeutic Area Focus

2 marketed9 pipeline

1 marketed2 pipeline

1 marketed1 pipeline

1 marketed

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

NCT02796131Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Phase 1

NCT02226783D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

Phase 1

NCT05995899Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation

Phase 4

Ardelyx

About Ardelyx

Why Work Here

Key Products

Watch Out For

Products & Portfolio (2)

Key Products by Revenue

Pipeline & Clinical Trials

Open Jobs (0)

Visa Sponsorship